Avoiding statin myopathy: Understanding key drug interactions

Clinical Lipidology

Volumn 6, Issue 6, 2011, Pages 665-674

  Harper, Charles R ^a   Jacobson, Terry A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

cytochrome P450; drug interaction; HMG CoA reductase inhibitor; MDR1; multidrug resistance protein; myalgia; myopathy; OATP1B1; organic anion transporter protein; rhabdomyolysis; statin induced myopathy; statins; transporter protein

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; PITAVASTATIN; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG UPTAKE; DYSLIPIDEMIA; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MUSCLE DISEASE; MYOPATHY; POMEGRANATE JUICE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 82755161108     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.11.57     Document Type: Review

References (59)

1. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106, 1024-1028 (2002). (Pubitemid 34925341)
2. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther. 19, 403-414 (2005). (Pubitemid 43228152)
3. Sacks FM. Adherence to statin therapy: why arent we doing better? Am. J. Med. 113, 685-686 (2002). (Pubitemid 36015806)
4. Bouchard M-H, Dragomir A, Blais L, Berard A, Pilon D, Perreault S. Impact of adherence to statins on coronary artery disease in primary prevention. Br. J. Clin. Pharmacol. 63, 698-708 (2007). (Pubitemid 46753568)
5. Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92, K23-K29 (2003).
6. Silva M, Matthews ML, Jarvis C et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 29, 253-260 (2007). (Pubitemid 46661859)
7. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Inten. Med. 150, 858-868 (2009).
8. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413-428 (1999).
9. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998). (Pubitemid 28231501)
10. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 11, 323-332 (2010).
11. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42, 963-970 (2002). (Pubitemid 34920793)
12. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol. 94(9), 1140-1146 (2004 (Pubitemid 39424216)
13. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. 46, 49-53 (1998). (Pubitemid 28308424)
14. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63, 332-341 (1998). (Pubitemid 28182231)
15. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. 64, 58-65 (1998). (Pubitemid 28377331)
16. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 64, 177-182 (1998). (Pubitemid 28423853)
17. Siedlik PH, Olson SC, Yang BB, Stern RH. Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol. 39, 501-504 (1999). (Pubitemid 29356471)
18. Amsden GW, Kuye O, Wei GC. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol. 42, 444-449 (2002). (Pubitemid 34259779)
19. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64, 369-377 (1998). (Pubitemid 28473762)
20. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann. Pharmacother. 36, 1546-1549 (2002).
21. Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann. Inten. Med. 140(8), W31 (2004).
22. Group SC, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Eng. J. Med. 359, 789-799 (2008).
23. Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol. Lett. 93, 215-219 (1997). (Pubitemid 28055525)
24. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569-577 (2002). (Pubitemid 34218852)
25. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. Ther. 66, 118-127 (1999). (Pubitemid 29398847)
26. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br. J. Clin. Pharmacol. 58, 56-60 (2004). (Pubitemid 38901467)
27. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63, 397-402 (1998). (Pubitemid 28214962)
28. Rogers JD, Zhao J, Liu L et al. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin. Pharmacol. Ther. 66, 358-366 (1999). (Pubitemid 29494128)
29. Hidaka M, Okumura M, Fujita K et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab. Dispos. 33, 644-648 (2005). (Pubitemid 40593878)
30. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am. J. Cardiol. 98, 705-706 (2006). (Pubitemid 44233475)
31. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56, 225-229 (2000). (Pubitemid 30456682)
32. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425-446 (2006). (Pubitemid 43363338)
33. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705 (2009).
34. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366 (2006). (Pubitemid 44465886)
35. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 82, 726-733 (2007). (Pubitemid 350114817)
36. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873-879 (2006). (Pubitemid 44772805)
37. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
38. Ho RH, Tirona RG, Leake BF et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
39. Lemahieu WP, Hermann M, Asberg A et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am. J. Transplant. 5, 2236-2243 (2005). (Pubitemid 41648471)
40. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 65, 410-413 (1993). (Pubitemid 23321239)
41. Olbricht C, Wanner C, Eisenhauer T et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62, 311-321 (1997). (Pubitemid 27417797)
42. Regazzi MB, Iacona I, Campana C et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 25, 2732-2734 (1993). (Pubitemid 23239614)
43. Asberg A. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs 63, 367-378 (2003). (Pubitemid 36259524)
44. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361(9374), 2024-2031 (2003). (Pubitemid 36695044)
45. Matsushima S, Maeda K, Kondo C et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314, 1059-1067 (2005). (Pubitemid 41205969)
46. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5, 703-729 (2009).
47. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18, 401-408 (2007). (Pubitemid 47051918)
48. Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Kim HS. Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability. Eur. J. Clin. Nutr. 65, 110-116 (2011).
49. Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340-345 (2001). (Pubitemid 32477075)
50. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76, 13 (1995).
51. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51, 2375-2384 (2008). (Pubitemid 351815163)
52. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am. J. Kidney Dis. 41(4 Suppl. 3), I-IV, S1-S91 (2003).
53. Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J. Clin. Hypertens. 8, 35-41 (2006).
54. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet. 41, 1195-1211 (2002). (Pubitemid 35398692)
55. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74, 1045-1052 (1992).
56. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect. Dis. 7, 787-796 (2007). (Pubitemid 350153668)
57. Winston A, Boffito M. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J. Antimicrob. Chemother. 56, 1-5 (2005). (Pubitemid 41418332)
58. Ray GM. Antiretroviral and statin drug-drug interactions. Cardiol. Rev. 17, 44-47 (2009).
59. Huang S-M, Lesko L, Temple R. Adverse drug reactions and interactions. In:Pharmacology and Therapeutics: Principles to Practice. Waldman SA, Terzic A (Eds). Elsevier, PA, USA, 271 (2009